Screener
Aquestive Therapeutics, Inc. AQST Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Royalty obligations, net | 27,835 | 25,941 |
| Liability related to the sale of future revenue, net | 61,168 | 62,023 |
| Lease liabilities | 7,525 | 4,337 |
| Deferred revenue, net of current portion | 18,845 | 19,390 |
| Other non-current liabilities | 6,185 | 7,269 |
| Total liabilities | 188,690 | 194,087 |
| Contingencies (Note 20) | ||
| Stockholders’ deficit: |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s contract liabilities?
- Aquestive Therapeutics, Inc. (AQST) reported contract liabilities of $18.85M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s contract liabilities changed year-over-year?
- Aquestive Therapeutics, Inc.'s contract liabilities decreased by 5.5% year-over-year, from $19.94M to $18.85M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s contract liabilities?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s contract liabilities has grown at a 39.8% compound annual growth rate (CAGR), from $3.63M to $19.39M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Aquestive Therapeutics, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude